Rheumatic and musculoskeletal diseases (RMDs) are a class of autoimmune diseases that invade multiple tissues, systems, and internal organs, with varying degrees of immune-inflammatory responses. Due to the poor blood circulation of the patient, the nutrients needed by the muscles or tissues cannot be transported through the blood circulation, resulting in the lack of nutrients in the muscles of the patients and accelerated aging and stiffness. In severe cases, the muscles and blood vessels of the patients will atrophy, and some patients may suffer from joint damage. Disability and visceral failure seriously affect normal function, have a high disability rate, and bring a heavy burden to the patient's family and society.
During treatment, anti-inflammatory therapy and correction of immune system disturbances play a major role in RMDs. Although great progress has been made in the etiology and new drug discovery of RMDs in the past few years, their therapeutic effects still need to be improved. A better understanding of the relationship between inflammation and immunity in RMDs, and the impact of these diseases on cell subsets and cytokines, can help us better understand the pathogenesis of RMDs.
The main purpose of this Research Topic is to collect Original Research articles, Reviews, Mini-Reviews, and Perspectives that summarize and explore new therapeutic targets for autoimmune inflammatory diseases and elucidate their underlying pathogenesis and mechanisms.
We aim to summarize the latest progress in this field, with highlights including but not limited to:
1. Changes of inflammatory cytokines or immune indicators in RMDs;
2. Inflammatory mechanism and therapeutic effect of new drugs on RMDs;
3. The influence of lymphocyte population on the internal inflammatory environment of RMDs;
4. Novel gene targets and inflammatory signaling pathways of RMDs.
Rheumatic and musculoskeletal diseases (RMDs) are a class of autoimmune diseases that invade multiple tissues, systems, and internal organs, with varying degrees of immune-inflammatory responses. Due to the poor blood circulation of the patient, the nutrients needed by the muscles or tissues cannot be transported through the blood circulation, resulting in the lack of nutrients in the muscles of the patients and accelerated aging and stiffness. In severe cases, the muscles and blood vessels of the patients will atrophy, and some patients may suffer from joint damage. Disability and visceral failure seriously affect normal function, have a high disability rate, and bring a heavy burden to the patient's family and society.
During treatment, anti-inflammatory therapy and correction of immune system disturbances play a major role in RMDs. Although great progress has been made in the etiology and new drug discovery of RMDs in the past few years, their therapeutic effects still need to be improved. A better understanding of the relationship between inflammation and immunity in RMDs, and the impact of these diseases on cell subsets and cytokines, can help us better understand the pathogenesis of RMDs.
The main purpose of this Research Topic is to collect Original Research articles, Reviews, Mini-Reviews, and Perspectives that summarize and explore new therapeutic targets for autoimmune inflammatory diseases and elucidate their underlying pathogenesis and mechanisms.
We aim to summarize the latest progress in this field, with highlights including but not limited to:
1. Changes of inflammatory cytokines or immune indicators in RMDs;
2. Inflammatory mechanism and therapeutic effect of new drugs on RMDs;
3. The influence of lymphocyte population on the internal inflammatory environment of RMDs;
4. Novel gene targets and inflammatory signaling pathways of RMDs.
